SOURCE: Threshold Pharmaceuticals

September 15, 2005 17:24 ET

Threshold Pharmaceuticals Appoints Michael Ostrach Chief Operating Officer and General Counsel

REDWOOD CITY, CA -- (MARKET WIRE) -- September 15, 2005 -- Threshold Pharmaceuticals (NASDAQ: THLD) today announced the appointment of Michael Ostrach to the position of chief operating officer and general counsel. In a newly created position, Mr. Ostrach will be responsible for providing leadership and strategic direction to Threshold's business development, legal affairs, finance, and investor and corporate communications activities.

Mr. Ostrach has more than twenty years of experience as a biotechnology executive, with responsibility for corporate and business development, finance, investor relations and legal affairs. From 1997 to 2004, Mr. Ostrach served in several positions at Kosan Biosciences, most recently as president and chief operating officer. Prior to that, Mr. Ostrach was executive vice president and chief operating officer of Neurobiological Technologies and before that he was president of Chiron Technologies. He began his corporate career at Cetus Corporation, initially as general counsel and then as senior vice president of corporate affairs, general counsel and secretary. Mr. Ostrach received his J.D. from Stanford Law School and his B.A. from Brown University.

"I am delighted that Michael has chosen to join our management team. He brings to Threshold a breadth of experience ideally suited to our needs as we grow our organization and advance products through clinical development and toward commercialization. His experience and stature in the biotechnology industry will be extremely valuable to Threshold," said Barry Selick, Threshold's chief executive officer.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics based on Metabolic Targeting, an approach that offers broad potential to treat most solid tumors and certain other diseases. By selectively targeting tumor and certain other diseased cells, Threshold's pipeline of drug candidates holds promise to be more effective and less toxic to healthy tissues than conventional drugs. Threshold's initial clinical focus is the treatment of cancer and benign prostatic hyperplasia, or BPH, a disease afflicting tens of millions of men worldwide. For additional information, please visit http://www.thresholdpharm.com.

Contact Information

  • Investor Contact Information:
    Denise T. Powell
    Threshold Pharmaceuticals
    650-474-8206
    Email Contact

    Media Contact Information:
    Chris Norris
    Access Communications
    415-844-6285
    Email Contact